Michael Heltzen insider trades
Open-market stock purchases and sales by Michael Heltzen, Chief Executive Officer at Exozymes Inc, from SEC Form 4 filings since Nov 15, 2024.
Track record: 33% of 9 scored buys are up 5% or more since purchase, averaging -16%.